Logo
Prostrolane Inner B SE 1 x 2 ml

Prostrolane Inner B SE 1 x 2 ml

Prostrolane

Aesthetic medicine injectable (medical device)
  • CE Marked medical device for aesthetic use in the European market
  • Manufactured by Caregen Co., Ltd. under ISO 13485 Compliant quality management for medical devices
  • Manufactured under ISO 9001 and ISO 14001 quality and environmental management standards (Caregen corporate certifications)
Periorbital mesotherapy / peptide-based lipolytic filler for under-eye area

Description

Prostrolane Inner B SE is an injectable gel for professional medical use, developed by Caregen for non-surgical correction of the periorbital (under-eye) area. It combines 0.7% sodium hyaluronate with a complex of four biomimetic peptides (Nonapeptide-32, Pentapeptide-43, Tripeptide-41, Octapeptide-11) in a prolonged-release system. The product is designed to reduce infraorbital fat pads and malar bags, improve edema and lymphatic stagnation, soften skin surface irregularities, brighten dark circles and increase skin firmness and elasticity around the eyes. By promoting lipolysis and inhibiting new fat formation while stimulating collagen synthesis and tissue hydration, Prostrolane Inner B SE provides gradual, natural-looking rejuvenation of the under-eye area over several weeks.

Bnefits

  • Reduces under-eye and malar fat bags and puffiness
  • Improves lymphatic drainage and decreases periorbital edema
  • Softens skin surface irregularities and smooths the orbital contour
  • Brightens dark circles and improves overall tone around the eyes
  • Increases skin elasticity and turgor via peptide-stimulated collagen synthesis
  • Provides prolonged, gradual effect due to sustained-release peptide technology
  • Hydrates periocular tissues through sodium hyaluronate content
  • Non-surgical treatment option for eye bags, with minimally invasive injections

Indications

  • Periorbital and malar fat bags under the eyes
  • Puffiness and swelling (lymphostasis, pastosity) of the lower eyelids
  • Dark circles and dull skin tone in the periocular region
  • Low skin tone and elasticity under the eyes
  • Fine lines, crow’s feet and age-related wrinkles around the eyes
  • Unnatural folds and uneven relief of the lower eyelid/cheek junction
  • Adjunctive treatment and preparation before lower blepharoplasty
  • Mild periorbital herniation where non-surgical correction is appropriate

Composition

  • Sodium Hyaluronate 0.7%
  • PBS (Phosphate Buffered Saline)
  • Nonapeptide-32
  • Pentapeptide-43
  • Tripeptide-41
  • Octapeptide-11

Formulation

  • Sterile injectable gel for periorbital use
  • Non-animal origin biomimetic peptide complex
  • 0.7% hyaluronic acid (sodium hyaluronate) in phosphate-buffered saline
  • Prolonged-release peptide technology providing sustained activity for approximately 2 weeks after injection

Packaging

  • Carton containing 1 pre-filled glass syringe x 2 ml (professional pack size on this listing; other distributors may supply 2 x 1 ml syringes)
  • Sterile, single-use syringe without needles (needles to be purchased separately)
  • Intended for use only by qualified healthcare professionals

Usage

  • For professional medical use only; must be administered by a suitably qualified healthcare practitioner experienced in periocular injections.
  • Indicated injection plane: deep dermis or superficial subcutaneous tissue of the periorbital/infraorbital area, following the manufacturer’s injection protocol.
  • Typical needle choice: 27G x 13 mm or 30G x 13 mm needle, or appropriate micro-cannula, according to practitioner preference and local regulations.
  • Standard treatment protocol: usually 2–4 sessions spaced about 2 weeks apart, depending on severity of under-eye bags and patient response.
  • Recommended volume: small aliquots (e.g. 0.1–0.2 ml per injection point) evenly distributed along the infraorbital/malar region; total volume per session adjusted to individual anatomy and tolerance.
  • After injection, gentle massage or molding may be performed according to the protocol to distribute the product and avoid nodules.
  • Post-treatment advice typically includes avoiding makeup on the treated area for the first 24 hours, and avoiding intense heat exposure (sauna, steam bath, sunbed) and strenuous exercise for several days as per clinic protocol.
  • Patients should be monitored for early adverse events (redness, swelling, bruising, pain, nodules) and instructed to contact the clinic immediately if severe or persistent symptoms occur.

Contraindications

  • Known hypersensitivity or allergy to hyaluronic acid, peptides, or any component of the formulation
  • Acute or chronic skin diseases, inflammatory lesions, active dermatoses or infections (including active herpes) at or near the intended injection site
  • Autoimmune diseases or significant immune system disorders, particularly those affecting connective tissues or healing
  • Uncontrolled diabetes mellitus
  • Known coagulation disorders or use of anticoagulant/antiplatelet therapy where injection-related bleeding risk is unacceptable
  • History of severe allergic reactions or anaphylaxis
  • Current oncologic disease or ongoing cancer therapy, unless specifically approved by the treating oncologist
  • Pregnancy and breastfeeding
  • Age under 18 years
  • Any other contraindication to injectable aesthetic procedures as determined by the treating physician

Adverse Effects

  • Transient erythema (redness), swelling and tenderness at the injection site
  • Bruising or hematoma in the treated area
  • Mild pain or discomfort during and shortly after injection
  • Temporary edema or increased puffiness in the periorbital region in the first days post-treatment
  • Palpable small nodules or irregularities if product is placed too superficially or unevenly (usually resolving with massage or over time)
  • Rarely, infection, inflammatory reactions or prolonged induration at the injection site
  • Very rare but serious complications associated with periocular injections (e.g. vascular compromise, visual disturbances) if improperly administered; emergency protocols must be in place

Storage Conditions

  • Store in accordance with the instructions on the original carton and package insert.
  • Keep in a clean, dry place at controlled room or cool storage temperature as specified by the manufacturer (commonly in the range used for hyaluronic acid medical devices).
  • Do not freeze and do not expose to excessive heat or direct sunlight.
  • Keep the syringe in its original blister and outer carton until use to maintain sterility and protect from light.
  • Keep out of reach of children and unauthorized persons.

Duration

A typical course consists of 2\u20134 treatment sessions at 2-week intervals (approximately 4\u20138 weeks total). Clinical improvement may persist for several months, after which maintenance treatments can be performed according to the practitioner\u2019s assessment.

Onset

Mild improvement is often visible shortly after the first session, but the main effect is progressive and becomes more evident about 1\u20132 weeks after each treatment; optimal results are usually seen around two weeks after the second session.

Browse more Aesthetic medicine injectable (medical device)

Top Treatments

Top Cities in the UK